Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
25.7M
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
23.9M
-
Shares change
-
+1.09M
-
Total reported value, excl. options
-
$364M
-
Value change
-
+$11.4M
-
Put/Call ratio
-
0.03
-
Number of buys
-
52
-
Number of sells
-
-42
-
Price
-
$15.21
Significant Holders of Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) as of Q1 2025
125 filings reported holding TRML - Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share as of Q1 2025.
Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.9M shares
of 25.7M outstanding shares and own 93.3% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (2.54M shares), Avoro Capital Advisors LLC (2.43M shares), BlackRock, Inc. (1.79M shares), TCG Crossover Management, LLC (1.48M shares), QVT Financial LP (1.47M shares), Pfizer Inc (1.27M shares), VANGUARD GROUP INC (1.19M shares), Blue Owl Capital Holdings LP (1.04M shares), Octagon Capital Advisors LP (905K shares), and QIMING U.S. VENTURES MANAGEMENT, LLC (742K shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.